[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2162466T3 - Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2162466T3
ES2162466T3 ES98940218T ES98940218T ES2162466T3 ES 2162466 T3 ES2162466 T3 ES 2162466T3 ES 98940218 T ES98940218 T ES 98940218T ES 98940218 T ES98940218 T ES 98940218T ES 2162466 T3 ES2162466 T3 ES 2162466T3
Authority
ES
Spain
Prior art keywords
group
substituted
alkyl
halogen
piridazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98940218T
Other languages
English (en)
Inventor
Ferrer Jordi Gracia
Crespo M Crespo
Noverola Armando Vega
Garcia Andres Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Application granted granted Critical
Publication of ES2162466T3 publication Critical patent/ES2162466T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (I) **fórmula** en la que: R1 representa un átomo de hidrógeno o un grupo -(CH2)m-Y, en el que m es un número entero de 0 a 4 e Y representa un grupo alquilo C1-C6, grupohalógenoalquilo C1-6, grupo alcoxi C1-C6, grupo alcoxicarbonilo que tiene hasta 7 átomos de carbono, grupo cicloalquilo C3-C7, grupo norbornilo o grupo fenilalquenilo que tiene hasta 12 átomos de carbono, o un grupo fenilo o piridilo que puede no estar sustituido o estar sustituido con uno o más átomos de halógeno; R2 representa un grupo fenilo, naftilo o tienilo que puede no estar sustituido o estar sustituido con uno o más átomos de halógeno o grupos alquilo C1-C6, alcoxi C1-C6, cicloalcoxi C3-C6, metilendioxi, nitro, dialquil (C1-C6)-amino o tri uorometilo; y R3 representa un átomo de hidrógeno o halógeno o un grupo alquilo C1-C6, y sus sales farmacéuticamente aceptables.
ES98940218T 1997-07-29 1998-07-13 Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2162466T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009701670A ES2137113B1 (es) 1997-07-29 1997-07-29 Nuevos derivados de triazolo-piridazinas heterociclicos.

Publications (1)

Publication Number Publication Date
ES2162466T3 true ES2162466T3 (es) 2001-12-16

Family

ID=8300216

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009701670A Expired - Lifetime ES2137113B1 (es) 1997-07-29 1997-07-29 Nuevos derivados de triazolo-piridazinas heterociclicos.
ES98940218T Expired - Lifetime ES2162466T3 (es) 1997-07-29 1998-07-13 Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES009701670A Expired - Lifetime ES2137113B1 (es) 1997-07-29 1997-07-29 Nuevos derivados de triazolo-piridazinas heterociclicos.

Country Status (36)

Country Link
US (2) US6407108B1 (es)
EP (1) EP1001955B1 (es)
JP (1) JP4320118B2 (es)
KR (1) KR20010022353A (es)
CN (1) CN1135231C (es)
AR (1) AR015927A1 (es)
AT (1) ATE207069T1 (es)
AU (1) AU737709B2 (es)
BG (1) BG64448B1 (es)
BR (1) BR9810829B1 (es)
CA (1) CA2298935A1 (es)
CO (1) CO4970780A1 (es)
CZ (1) CZ290208B6 (es)
DE (1) DE69802100T2 (es)
DK (1) DK1001955T3 (es)
EE (1) EE04313B1 (es)
EG (1) EG24041A (es)
ES (2) ES2137113B1 (es)
HK (1) HK1024914A1 (es)
HU (1) HUP0004708A3 (es)
ID (1) ID24506A (es)
IL (1) IL134081A (es)
MY (1) MY118796A (es)
NO (1) NO315118B1 (es)
NZ (1) NZ502356A (es)
PE (1) PE111099A1 (es)
PL (1) PL191031B1 (es)
PT (1) PT1001955E (es)
RU (1) RU2202552C2 (es)
SI (1) SI1001955T1 (es)
SK (1) SK284046B6 (es)
TR (1) TR200000243T2 (es)
TW (1) TW542837B (es)
UA (1) UA60339C2 (es)
WO (1) WO1999006404A1 (es)
ZA (1) ZA986248B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
HU229439B1 (hu) 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
WO2002080974A1 (fr) * 2001-04-04 2002-10-17 Sankyo Company, Limited Utilisation medicale d'inhibiteur de production de cytokine
WO2003024489A2 (en) 2001-09-19 2003-03-27 Altana Pharma Ag Combination of a nsaid and a pde-4 inhibitor
FR2832711B1 (fr) * 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
US7608716B2 (en) 2002-11-06 2009-10-27 Aska Pharmaceutical Co., Ltd. Pyrazolonaphthyridine derivative
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
RU2246496C1 (ru) * 2003-09-12 2005-02-20 Тец Виктор Вениаминович Вещество с противовирусной и антибактериальной активностью на основе производных 2,8-дитиоксо-1h-пирано[2,3-d, 6,5-d`] дипиримидина и их 10-аза-аналогов
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
NZ563423A (en) * 2005-06-10 2010-05-28 Merck Sharp & Dohme Inhibitors of AKT activity
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
KR20080046728A (ko) 2005-09-15 2008-05-27 아스카 세이야쿠 가부시키가이샤 복소환 화합물, 그의 제조 방법 및 용도
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2497470B8 (en) 2006-11-22 2015-12-02 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
US20110112079A1 (en) * 2008-01-09 2011-05-12 Thomas Craig J Phosphodiesterase inhibitors
MY187131A (en) 2008-05-21 2021-09-02 Incyte Corp Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
KR20120111739A (ko) 2009-12-31 2012-10-10 센트로 내셔널 드 인베스티가시오네스 온콜로지카스 (씨엔아이오) 키나제 억제제로서의 사용을 위한 삼환식 화합물
ES2608329T3 (es) 2010-02-03 2017-04-07 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3122670A1 (de) 1981-06-06 1982-12-23 Dr. Karl Thomae Gmbh, 7950 Biberach "neue 1,4,9,10-tetrahydro-pyrazolo(4,3-e) pyrido(3,2-b)(1,4)diazepin-10-one, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen"
FI81350C (fi) * 1982-01-18 1990-10-10 Lepetit Spa Analogfoerfarande foer framstaellning av nya, farmakologiskt aktiva 6-substituerade s-triatsolo/3,4-a/ ftalazinderivat.
JP3120857B2 (ja) * 1990-02-19 2000-12-25 中外製薬株式会社 新規な縮合複素環化合物とこれを用いた抗喘息剤
IL103388A (en) * 1991-10-09 1997-09-30 Syntex Inc PYRIDO £2,3-d| PYRIDAZINONES AND PYRIDAZINETHIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds

Also Published As

Publication number Publication date
NO20000394L (no) 2000-03-27
CZ290208B6 (cs) 2002-06-12
ID24506A (id) 2000-07-20
ES2137113A1 (es) 1999-12-01
HUP0004708A2 (hu) 2001-07-30
WO1999006404A1 (en) 1999-02-11
BR9810829A (pt) 2000-07-25
CA2298935A1 (en) 1999-02-11
JP2001512121A (ja) 2001-08-21
BG104112A (en) 2001-01-31
EP1001955B1 (en) 2001-10-17
ATE207069T1 (de) 2001-11-15
JP4320118B2 (ja) 2009-08-26
RU2202552C2 (ru) 2003-04-20
EP1001955A1 (en) 2000-05-24
DE69802100T2 (de) 2002-03-14
PL191031B1 (pl) 2006-03-31
UA60339C2 (uk) 2003-10-15
KR20010022353A (ko) 2001-03-15
NO20000394D0 (no) 2000-01-26
BR9810829B1 (pt) 2009-08-11
EG24041A (en) 2008-04-03
BG64448B1 (en) 2005-02-28
PE111099A1 (es) 1999-11-18
US20020183326A1 (en) 2002-12-05
PT1001955E (pt) 2002-02-28
CN1135231C (zh) 2004-01-21
HUP0004708A3 (en) 2002-11-28
CZ2000333A3 (cs) 2000-05-17
EE04313B1 (et) 2004-06-15
IL134081A (en) 2004-02-08
HK1024914A1 (en) 2000-10-27
TR200000243T2 (tr) 2000-07-21
CN1266434A (zh) 2000-09-13
NO315118B1 (no) 2003-07-14
DE69802100D1 (de) 2001-11-22
ZA986248B (en) 1999-02-05
SK862000A3 (en) 2000-07-11
NZ502356A (en) 2001-03-30
US6407108B1 (en) 2002-06-18
AU737709B2 (en) 2001-08-30
IL134081A0 (en) 2001-04-30
TW542837B (en) 2003-07-21
DK1001955T3 (da) 2001-11-19
AU8861298A (en) 1999-02-22
AR015927A1 (es) 2001-05-30
SK284046B6 (sk) 2004-08-03
MY118796A (en) 2005-01-31
ES2137113B1 (es) 2000-09-16
SI1001955T1 (en) 2002-02-28
PL338214A1 (en) 2000-10-09
CO4970780A1 (es) 2000-11-07
EE200000052A (et) 2000-10-16

Similar Documents

Publication Publication Date Title
ES2162466T3 (es) Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen.
AR018634A1 (es) Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
AR036093A1 (es) Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios
FI954105A (fi) Uusia 4-aminopyridiinejä, niiden valmistusmenetelmä sekä näitä yhdisteitä sisältäviä lääkkeitä
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
UY26727A1 (es) Derivados de tropano útiles en terapia
ES2080815T3 (es) Derivados de la 1-naftil-piperacina, sus procedimientos de preparacion y composiciones farmaceuticas que los contienen.
DK0499521T3 (da) Hidtil ukendte N-myristoyltransferaseinhibitorer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
HUP0003826A2 (hu) Új triazolo [4,5-d] pirimidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
NO812355L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater
AR035821A1 (es) Composiciones que contienen un compuesto imidazotriazinona y al menos un anestesico local para administracion nasal, el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de la disfuncion erectil masculina , un aplicador de pulverizacion nasal y un insuflador de polvo
AR027335A1 (es) Compuestos de piperidina-4-sulfonamida, proceso de preparacion de los mismos, y composiciones farmaceuticas que los contienen
MX9400253A (es) Derivados de piperazina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
CO4340737A1 (es) Acidos 5-vinil-y- 5-etinil-quinolon- y naftiridon carboxili- cos
AR041376A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
ATE199909T1 (de) Derivate der phosphonsäure, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten
DK1381370T3 (da) N-Biphenylcarbonyl- og N-phenylpyridylcarbonyl-substituerede bi- og tricykliske azepiner og diazepiner som vasopressin-agonister
HUP0303457A2 (hu) Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk
MY159418A (en) New derivatives of flavones, their preparation process, their use as medicaments, pharmaceutical compositions and new use
AR002259A1 (es) Derivados de 1-oxo-2-(fenilsulfonilamino)pentilpiperidina, su preparacion, compuestos intermedios y composicion que contiene a dichos derivados.
NO993225L (no) Farnesyltransferaseinhibitorer
ES2036528T3 (es) Procedimiento para la obtencion de derivados aromaticos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1001955

Country of ref document: ES